Published in Health Business Week, February 22nd, 2008
"To examine the long-term safety of levalbuterol hydrofluoroalkane (HFA) vs racemic albuterol HFA administered via metered-dose inhaler (MDI) in patients with stable asthma. Patients with mild to moderate asthma (mean forced expiratory volume in 1 second [FEV1], 68.3% of predicted) 12 years or older participated in a multicenter, parallel-group, open-label study....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.